Ivonescimab

Name: Ivonescimab in EGFR-mutated non-small-cell lung cancer: Prevalence of EGFR-mutated non-small-cell lung cancer
Published: 2026-09-14T15:39:06-04:00

EGFR-mutated non-small-cell lung cancer

Manufacturer: Summit Therapeutics
Regulatory submission: BLA submitted in the fourth quarter of 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Epidemiology

Prevalence of EGFR-mutated non-small-cell lung cancer

1 evidence topic · 1 source

Proportion of NSCLC cases with an EGFR mutation

“An estimated 10–15% of non-small cell lung cancer (NSCLC) cases present with epidermal growth factor receptor mutation (EGFRm).” (opens the source at this quote in a new tab)